NEW MJ NEWS

Cresco Labs Reports Fourth Quarter & Full Year 2023 Financial Results Demonstrating Significant Profitability and Cash Flow Improvements

Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, today released its financial and operating results for the fourth quarter and year ended December 31, 2023. All financial information presented in this release is reported in accordance with U.S. GAAP and in U.S. dollars, unless otherwise indicated, and is available on the Company’s investor website, here.

Fourth Quarter 2023 Highlights

Fourth quarter revenue of $188 million, excluding the impact from strategic divestitures aimed to drive profitability, down 2% year-over-year.

Gross profit of $96 million. Adjusted gross profit1 up 12% year-over-year to $100 million, or 53% of revenue, an 850 bps improvement.

SG&A of $57 million. Removed $54 million in annualized Adjusted SG&A1, reducing Adjusted SG&A1 by 20% year-over-year to $55 million, or 29% of revenue.

Fourth quarter net income of $5 million.

Fourth quarter adjusted EBITDA1 nearly doubled year-over-year to $55 million, or 29% of revenue, a 1,400 bps improvement.

Retained the No. 1 share position in Illinois, Pennsylvania and Massachusetts2.

Fiscal Year 2023 Highlights

Revenue of $771 million.

Adjusted gross profit1 of $377 million, or 49% of revenue.

Driven by the Year-of-the-Core strategy, adjusted SG&A1 decreased by $35 million and adjusted EBITDA margin1 rose by over 200 bps.

Adjusted EBITDA1 of $174 million, or 23% of revenue.

Net loss of $180 million for the full year which included $151 million of impairment charges.

Generated $59 million in operating cash flows for the full year, and ended the year with $109 million of cash, cash equivalents and restricted cash.

1 See “Non-GAAP Financial Measures” at the end of this press release for more information regarding the Company’s use of non-GAAP financial measures.
2 According to BDSA.

Management Commentary

“I’m proud to share that our Q4 results capped off the Year of the Core with strong bottom-line growth and margin expansion, nearly doubling our Adjusted EBITDA and achieving positive free cash flow for the year. We’ve set a new standard for ourselves, making this focus on our core part of our DNA moving forward and we’re using these wins to fuel our business and capitalize on the many growth catalysts ahead.

Everything we did in 2023 was designed to prepare us to take advantage of the monumental opportunities ahead, including; maximizing our upcoming adult-use catalysts, capitalizing on our brands and winning with independents, and expanding our retail to provide the consumer with the best cannabis experience possible,” said Charles Bachtell, CEO of Cresco Labs.

Balance Sheet, Liquidity and Other Financial Information

As of December 31, 2023, current assets were $278 million, including cash, cash equivalents and restricted cash of $109 million. The Company had senior secured term loan debt, net of discount and issuance costs, of $386 million and a mortgage loan, net of discount and issuance costs of $18 million.

Total shares on a fully converted basis to Subordinate Voting Shares were 467,871,956 as of December 31, 2023.

Conference Call and Webcast

The Company will host a conference call and webcast to discuss its financial results on Wednesday, March 13, 2024, at 8:30am Eastern Time (7:30am Central Time). The conference call may be accessed via webcast or by dialing 1-833-470-1428 (US Toll Free) or 1-404-975-4839 (US Local), providing access code 614771. Archived access to the webcast will be available for one year on Cresco Labs’ investor website.

Consolidated Financial Statements

The financial information reported in this press release is based on unaudited management prepared financial statements for the three months and year ended December 31, 2023. These financial statements have been prepared in accordance with U.S. GAAP. This release contains certain preliminary financial results for the three months and year ended December 31, 2023. These preliminary results for the three months and year ended December 31, 2023, are provided prior to completion of all internal reviews and external audit procedures, and are therefore subject to adjustment until the filing of the Company’s audited consolidated financial statements, which the Company expects to file on SEDAR+ and EDGAR on or about March 14, 2024. The audit of the consolidated financial statements for the year ended December 31, 2023, is currently in process. All financial information contained in this press release is qualified in its entirety with reference to such financial statements. While the Company does not expect there to be any material changes between the information contained in this press release and the consolidated financial statements it files on SEDAR+ and EDGAR, to the extent that the financial information contained in this press release is inconsistent with the information contained in the Company’s financial statements, the financial information contained in this press release shall be deemed to be modified or superseded by the Company’s filed financial statements. The making of a modifying or superseding statement shall not be deemed an admission, for any purposes, that the modified or superseded statement, when made, constituted a misrepresentation for purposes of applicable securities laws. Further, the reader should refer to the additional disclosures in the Company’s audited financial statements for the year ended December 31, 2023, filed on SEDAR+ and EDGAR.

Cresco Labs references certain non-GAAP financial measures throughout this press release, which may not be comparable to similar measures presented by other issuers. Please see the “Non-GAAP Financial Measures” section below for more detailed information.

Non-GAAP Financial Measures

Earnings before interest, taxes, depreciation and amortization (“EBITDA”), Adjusted EBITDA, Adjusted EBITDA margin, Adjusted gross profit, Adjusted gross margin, Adjusted Selling, general and administrative (“Adjusted SG&A”) and Free Cash Flow are non-GAAP financial measures and do not have standardized definitions under U.S. GAAP. The Company has provided the non-GAAP financial measures, which are not calculated or presented in accordance with U.S. GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with U.S. GAAP and may not be comparable to similar measures presented by other issuers. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believe that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. These supplemental non-GAAP financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the U.S. GAAP financial measures presented herein. Accordingly, the Company has included below reconciliations of the supplemental non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with U.S. GAAP.

About Cresco Labs Inc.

Cresco Labs’ mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy’s and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs’ journey by visiting www.crescolabs.com or following the Company on Facebook, X or LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking statements”). Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2023, expected to be filed on or about March 14, 2024, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.

Cresco Labs Inc.

Financial Information and Non-GAAP Reconciliations

(All amounts expressed in thousands of U.S. Dollars)

Consolidated Statements of Operations

For the Three Months Ended December 31, 2023, September 30, 2023 and December 31, 2022

and

Years Ended December 31, 2023 and December 31, 2022

For the Three Months Ended

For the Year Ended

($ in thousands)

December 31,
2023

September 30,
2023

December 31,
2022

December 31,
2023

December 31,
2022

(unaudited)

(unaudited)

(unaudited)

Revenues, net

$

188,237

$

190,559

$

199,580

$

770,885

$

842,681

Cost of goods sold

92,091

96,919

111,876

408,519

435,668

Gross profit

96,146

93,640

87,704

362,366

407,013

Gross profit %

51.1

%

49.1

%

43.9

%

47.0

%

48.3

%

Operating expenses:

Selling, general and administrative

56,767

62,484

80,193

261,710

310,353

Share-based compensation

2,278

3,479

4,319

12,924

19,664

Depreciation and amortization

9,978

5,942

6,016

24,538

20,636

Impairment loss

24

129,491

140,655

151,017

140,655

Total operating expenses

69,047

201,396

231,183

450,189

491,308

Income (loss) from operations

27,099

(107,756

)

(143,479

)

(87,823

)

(84,295

)

Other expense, net:

Interest expense, net

(14,331

)

(11,764

)

(15,904

)

(60,819

)

(57,837

)

Other income, net

50

329

2,521

1,740

15,227

Total other expense, net

(14,281

)

(11,435

)

(13,383

)

(59,079

)

(42,610

)

Income (loss) before income taxes

12,818

(119,191

)

(156,862

)

(146,902

)

(126,905

)

Income tax (expense) benefit

(7,950

)

5,746

(23,761

)

(32,950

)

(88,938

)

Net income (loss)1

$

4,868

$

(113,445

)

$

(180,623

)

$

(179,852

)

$

(215,843

)

1 Net income (loss) includes amounts attributable to non-controlling interests.

Cresco Labs Inc.

Unaudited Reconciliation of Gross Profit to Adjusted Gross Profit (Non-GAAP)

For the Three Months Ended December 31, 2023, September 30, 2023 and December 31, 2022

and

Years Ended December 31, 2023 and December 31, 2022

For the Three Months Ended

For the Year Ended

($ in thousands)

December 31,
2023

September 30,
2023

December 31,
2022

December 31,
2023

December 31,
2022

Revenues, net

$

188,237

$

190,559

$

199,580

$

770,885

$

842,681

Cost of goods sold1

92,091

96,919

111,876

408,519

435,668

Gross profit

$

96,146

$

93,640

$

87,704

$

362,366

$

407,013

Fair value mark-up for acquired inventory

5,466

Cost of goods sold adjustments for acquisition and other non-core costs

3,576

2,602

1,129

14,868

4,379

Adjusted gross profit (Non-GAAP)

$

99,722

$

96,242

$

88,833

$

377,234

$

416,858

Adjusted gross profit % (Non-GAAP)

53.0

%

50.5

%

44.5

%

48.9

%

49.5

%

1 Production (cultivation, manufacturing and processing) costs related to products sold during the period.

Cresco Labs Inc.

Summarized Consolidated Statements of Financial Position

As of December 31, 2023 and December 31, 2022

($ in thousands)

December 31,
2023

December 31,
2022

Cash, cash equivalents and restricted cash

$

108,520

$

121,510

Other current assets

169,567

204,536

Property and equipment, net

368,308

379,722

Intangible assets, net

296,966

407,590

Goodwill

279,697

330,555

Other non-current assets

135,409

139,779

Total assets

$

1,358,467

$

1,583,692

Total current liabilities

$

200,242

$

255,865

Total non-current liabilities

730,158

740,144

Total shareholders’ equity

428,067

587,683

Total liabilities and shareholders’ equity

$

1,358,467

$

1,583,692

Cresco Labs Inc.

Unaudited Reconciliation of SG&A to Adjusted SG&A (Non-GAAP)

For the Three Months Ended December 31, 2023, September 30, 2023 and December 31, 2022

and

Years Ended December 31, 2023 and December 31, 2022

For the Three Months Ended

For the Year Ended

($ in thousands)

December 31,
2023

September 30,
2023

December 31,
2022

December 31,
2023

December 31,
2022

Selling, general and administrative

$

56,767

$

62,484

$

80,193

$

261,710

$

310,353

Adjustments for acquisition and other non-core costs

2,242

5,458

12,168

21,175

35,186

Adjusted SG&A (Non-GAAP)

$

54,525

$

57,026

$

68,025

$

240,535

$

275,167

Cresco Labs Inc.

Unaudited Reconciliation of Net Income to Adjusted EBITDA (Non-GAAP)

For the Three Months Ended December 31, 2023, September 30, 2023 and December 31, 2022

and

Years Ended December 31, 2023 and December 31, 2022

For the Three Months Ended

For the Year Ended

($ in thousands)

December 31,
2023

September 30,
2023

December 31,
2022

December 31,
2023

December 31,
2022

Net income (loss)1

$

4,868

$

(113,445

)

$

(180,623

)

$

(179,852

)

$

(215,843

)

Depreciation and amortization

20,252

15,297

14,462

62,512

51,930

Interest expense, net

14,331

11,764

15,904

60,819

57,837

Income tax expense (benefit)

7,950

(5,746

)

23,761

32,950

88,938

EBITDA (Non-GAAP)

$

47,401

$

(92,130

)

$

(126,496

)

$

(23,571

)

$

(17,138

)

Other income, net

(50

)

(329

)

(2,521

)

(1,740

)

(15,227

)

Fair value mark-up for acquired inventory

5,466

Adjustments for acquisition and other non-core costs

4,434

7,942

12,714

31,570

35,732

Impairment loss

24

129,491

140,655

151,017

140,655

Share-based compensation

3,017

4,072

5,271

16,356

23,221

Adjusted EBITDA (Non-GAAP)

$

54,826

$

49,046

$

29,623

$

173,632

$

172,709

1 Net income (loss) includes amounts attributable to non-controlling interests.

Cresco Labs Inc.

Summarized Consolidated Statements of Cash Flows

For the Three Months Ended December 31, 2023, September 30, 2023 and December 31, 2022

and

Years Ended December 31, 2023 and December 31, 2022

For the Three Months Ended

For the Year Ended

($ in thousands)

December 31,
2023

September 30,
2023

December 31,
2022

December 31,
2023

December 31,
2022

(unaudited)

(unaudited)

(unaudited)

Net cash (used in) provided by operating activities

$

(3,301

)

$

40,622

$

3,631

$

58,564

$

18,741

Net cash provided by (used in) investing activities

2,609

(12,476

)

(12,454

)

(44,585

)

(36,577

)

Net cash (used in) provided by financing activities

(3,782

)

10,052

(2,031

)

(26,907

)

(86,643

)

Effect of foreign currency exchange rate changes on cash and cash equivalents

(22

)

7

44

(62

)

(113

)

Net change in cash and cash equivalents and restricted cash

$

(4,496

)

$

38,205

$

(10,810

)

$

(12,990

)

$

(104,592

)

Cash and cash equivalents and restricted cash, beginning of period

113,016

74,811

132,320

121,510

226,102

Cash and cash equivalents and restricted cash, end of period

$

108,520

$

113,016

$

121,510

$

108,520

$

121,510

Cresco Labs Inc.

Unaudited Reconciliation of Operating Cash Flow to Free Cash Flow (Non-GAAP)

For the Three Months Ended December 31, 2023, September 30, 2023 and December 31, 2022

and

Years Ended December 31, 2023 and December 31, 2022

For the Three Months Ended

For the Year Ended

($ in thousands)

December 31,
2023

September 30,
2023

December 31,
2022

December 31,
2023

December 31,
2022

Net cash (used in) provided by operating activities

$

(3,301

)

$

40,622

$

3,631

$

58,564

$

18,741

Purchases of property and equipment

(4,818

)

(12,452

)

(13,132

)

(55,385

)

(83,026

)

Proceeds from tenant improvement allowances

1,147

733

475

2,594

4,213

Free Cash Flow (Non-GAAP)

$

(6,972

)

$

28,903

$

(9,026

)

$

5,773

$

(60,072

)

View source version on businesswire.com: https://www.businesswire.com/news/home/20240313290673/en/

Contacts

Media
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
312-953-2767

Investors
TJ Cole, Cresco Labs
SVP, Corporate Development & Investor Relations
investors@crescolabs.com

For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

TILT Holdings Inc. (TLLTF) Reaches Agreement with Massachusetts Cannabis Control Commission

TILT Reaches Agreement with Massachusetts Cannabis Control Commission TILT Holdings Inc. (“TILT”…

Future Farm Technologies Inc. (FFRMF) Raises Over $2.5 Million Through Voluntary Warrant and Option Exercises

Future Farm Raises Over $2.5 Million Through Voluntary Warrant and Option Exercises…

Green Cures and Botanical Distribution Inc. (GRCU) Reviews Options in CBD Space with Purple Haze Properties

Green Cures & Botanical Distribution, Inc. Reviews Options in CBD Space with…